Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Non-Hodgkin's lymphomas.
Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F; National Comprehensive Cancer Network. Zelenetz AD, et al. Among authors: lacasce as. J Natl Compr Canc Netw. 2008 Apr;6(4):356-421. doi: 10.6004/jnccn.2008.0030. J Natl Compr Canc Netw. 2008. PMID: 18433606 No abstract available.
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Ryan CE, Brander DM, Barr PM, Tyekucheva S, Hackett LR, Collins MC, Fernandes SM, Ren Y, Zhou Y, McDonough MM, Walker HA, McEwan MR, Abramson JS, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR, Davids MS. Ryan CE, et al. Among authors: lacasce as. Leukemia. 2023 Apr;37(4):835-842. doi: 10.1038/s41375-023-01830-2. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717653 Clinical Trial.
Women in Lymphoma: A 4-year journey in promoting gender equity.
Trotman J, LaCasce A, Osborne W, Steiner A, Hawkes E, Casulo C; Women in Lymphoma Steering Committee. Trotman J, et al. Hematol Oncol. 2024 Nov;42(6):e3183. doi: 10.1002/hon.3183. Epub 2023 May 25. Hematol Oncol. 2024. PMID: 37231947 Free PMC article. No abstract available.
Improved survival in cHL with novel agents.
Merryman RW, LaCasce AS. Merryman RW, et al. Among authors: lacasce as. Blood. 2023 Jun 1;141(22):2666-2668. doi: 10.1182/blood.2023020068. Blood. 2023. PMID: 37261856 Free article. No abstract available.
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Jacene H, Park H, Dahi PB, Nieto Y, Joyce RM, Chen YB, Shipp MA, Herrera AF, Armand P. Merryman RW, et al. Among authors: lacasce as. Blood Adv. 2023 Sep 12;7(17):4748-4759. doi: 10.1182/bloodadvances.2022007706. Blood Adv. 2023. PMID: 36399518 Free PMC article.
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
Merrill MH, Dahi PB, Redd RA, McDonough MM, Chen YB, DeFilipp Z, Herrera AF, Fisher DC, LaCasce AS, Odejide OO, Ng SY, Jacobson CA, Merryman RW, Kim AI, Nieto YL, Sauter CS, Shah GL, Zain JM, Armand P, Jacobsen ED. Merrill MH, et al. Among authors: lacasce as. Blood. 2023 Aug 17;142(7):621-628. doi: 10.1182/blood.2023020244. Blood. 2023. PMID: 37319432 Free PMC article. Clinical Trial.
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J; National Comprehensive Cancer Network. Zelenetz AD, et al. Among authors: lacasce as. J Natl Compr Canc Netw. 2006 Mar;4(3):258-310. doi: 10.6004/jnccn.2006.0025. J Natl Compr Canc Netw. 2006. PMID: 16507273 No abstract available.
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD. Friedberg JW, et al. J Clin Oncol. 2008 Jan 10;26(2):204-10. doi: 10.1200/JCO.2007.12.5070. J Clin Oncol. 2008. PMID: 18182663 Clinical Trial.
182 results